
BIO-PATH HOLDINGS INC

Form 8-K July 01, 2016		
UNITED STATES		
SECURITIES AND EXCHANGE COMMISSION		
WASHINGTON, DC 20549		
FORM 8-K		
CURRENT REPORT PURSUANT		
TO SECTION 13 OR 15(d) OF THE		
SECURITIES EXCHANGE ACT OF 1934		
Date of report (Date of earliest event reported): June 28, 2016		
BIO-PATH HOLDINGS, INC.		
(Exact name of registrant as specified in its charter)		
Delaware	001-36333	87-0652870
(State or other jurisdiction of incorporation)	(Commission File Number	(IRS Employer Identification No.)

(Zip Code)

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401

(Address of principal executive offices)



Item 7.01 Regulation FD Disclosure.

On June 28, 2016, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer." A copy of such press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

99.1 Press Release dated June 28, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-PATH HOLDINGS, Inc.

Dated: June 30, 2016 By:/s/ Peter H. Nielsen
Peter H. Nielsen
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press Release dated June 28, 2016